
    
      This is a single center, open label, non-randomized, Phase 1, two-part study of ION537 in up
      to 102 participants. Part 1 of the study consists of sequential cohort, dose escalation in
      patients with advanced solid tumors. Part 2 is dose expansion in patients with molecularly
      selected advanced solid tumors. In total, the study includes up to 102 participants. The
      study will consist of a 30-day screening period, a treatment period consisting of sequential
      consecutive treatment cycles (each cycle will be of 28 days) and a post-treatment follow-up
      period of at least 28 days following the last dose of study drug.
    
  